Skip to main content
Premium Trial:

Request an Annual Quote

Real Time Genomics, Omicia Partner on Workflow to Interpret Clinical Genomics Data for Childhood Diseases

NEW YORK (GenomeWeb News) – Real Time Genomics and Omicia today announced a deal to integrate each other's platforms into a workflow for identifying disease-causing variants in whole genomes and exomes for the clinical interpretation of genomes for childhood diseases.

RTG's platform provides read alignments and variant detection from raw sequencing data from different sequencing platforms. As part of the deal, variants detected from the technology, reported as a DNA variant file, will be fed into Omicia's Opal engine for interpretation, resulting in a report for whole-genome sequences that can be clinically actionable. The companies said that the report can be delivered in hours, compared to days using other methods.

The integrated product will be launched later this year. Financial and other terms of the deal were not disclosed.

"RTG believes that partnering with Omicia will be of great value to biomedical and clinical researchers using genomics in their childhood disease efforts," RTG CEO Steve Lombardi said in a statement. "Our combined analysis and interpretation workflow can provide a simple, accurate approach to quickly identify the important variants, thereby removing an important bottleneck to the use of genomics in personalized medicine."

"For genomic testing to reach its full potential, we must simplify the analysis of complex sequence data and integrate this information with other routine tests to help diagnose disease and guide treatment decisions," Omicia CEO Mike Aicher added. "Through this partnership, Omicia is expanding its offering towards a more complete solution to bring researchers and clinicians better tools for translating genomic data into medically actionable information."

His firm announced a deal with Spiral Genetics last month, also leveraging the Opal system.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.